SHERPA/SISONKE 4
Open-label, phase 3 study to evaluate the effectiveness of heterologous mRNA-1273 boosting of the single or two dose Ad26.COV2.S COVID-19 vaccine among health care workers in South Africa.
Rationale
South Africa is severely affected by the global COVID-19 pandemic. As part of the Sisonke study, HCWs received a single dose of Ad26.COV2.S vaccine between 17 February and 17 May 2021, and were then offered a second dose between 8 November and 17 December 2021. Immunogenicity studies have since indicated that a heterologous mRNA vaccine boost strategy may elicit stronger neutralizing antibody responses among people who received the Ad26.COV2.S and other vector-based vaccines.
Investigators
- Dr Faeezah Patel , Principal Investigator
- Prof Lee Fairlie
- Dr Elizea Horne
- Dr Robert Kieser
- Tiffany Seef
- Othusiste Segalo
- Dr Mrinmayee Dhar
Latest Update
May 2023
For more about SHERPA/SISONKE 4 study please email rhicomms@wrhi.ac.za